Skip to main content

Table 6 Clinical and laboratory data evolution over two-year follow-up

From: Impact of superimposed nephrological care to guidelines-directed management by primary care physicians of patients with stable chronic kidney disease: a randomized controlled trial

Characteristics

PCP management only

Combined management

P*

 

T0 (N = 116)

T1 (N = 99)

T2 (N = 93)

T0 (N = 126)

T1 (N = 71)

T2 (N = 85)

 

Blood pressure measurement

 Office SBP (mmHg)

127 (26)

132 (33)

125 (43)

131 (23)

137 (19)

135 (26)

0.65

 Office DBP (mmHg)

72 (15)

71 (18)

69 (24)

74 (14)

78 (12)

75 (14)

0.31

 ABPM SBP (mmHg)

132 (24)

135 (27)

135 (17)

132 (17)

133 (15)

126 (43)

0.20

 ABPM DBP (mmHg)

74 (13)

73 (11)

75 (10)

79 (12)

78 (11)

76 (10)

0.20

Transthoracic ultrasound

 LVHa

31/97 (32%)

8/29 (28%)

4/29 (14%)

42/112 (38%)

22/62 (35%)

20/50 (40%)

0.22

 EF (%)

54 (14)

36 (27)

55 (17)

55 (17)

43 (29)

57 (16)

0.21

Laboratory data

 Creatinine (mmol/l)

175 (53)

203 (99)

221 (143)

176 (75)

184 (104)

212 (149)

0.45

 eGFR (ml/min)

34 (80)

32 (15)

31 (16)

34 (90)

35 (13)

32 (14)

0.65

 Hemoglobin* (g/l)

112 (17)

117 (18)

114 (26)

111 (20)

128 (20)

124 (30)

< 0.001

 Ferritin (g/l)

102 (60–188)

99 (41–241)

215 (88–494)

176 (81–405)

148 (74–267)

137 (82–234)

0.35

 Transferrin sat. (%)

24 (19)

24 (18)

27 (23)

21 (13)

26 (10)

23 (11)

0.44

 Calcium (mmol/l)

2.4 (0.2)

2.3 (0.4)

2.3 (0.4)

2.4 (0.2)

2.4 (0.1)

2.3 (0.4)

0.33

 Phosphate (mmol/l)

1.1 (0.3)

1.2 (0.2)

1.3 (0.4)

1.2 +/−0.2

1.2 +/− 0.2

1.3 +/− 0.3

0.57

 PTH* (pmol/l)

9 (7–13)

11 (8–17)

11 (8–32)

8 (4–14)

10 (6–13)

9 (5–15)

0.002

 Bicarbonate (mmol/l)

25 (5)

24 (6)

26 (6)

25 (5)

25 (4)

25 (4)

0.56

 Albumin (g/l)

29 (5.4)

34 (6)

33 (6)

35 (5)

35 (5)

36 (4)

0.19

 24-h proteinuria (g/l)

0.3 (0.2–3.8)

0.5 (0.1–2.0)

1.5 (0.3–5.3)

0.4 (0.2–1.0)

0.3 (0.1–1.2)

0.4 (0.2–1.1)

0.97

Medications

 RAS blockers

68 (59%)

36 (84%)

27 (68%)

92 (73%)

54 (82%)

49 (84%)

0.82

 Diuretics*

62 (53%)

34 (79%)

31 (78%)

81 (64%)

40 (61%)

40 (69%)

0.007

 Beta-blockers

70 (56%)

26 (60%)

22 (55%)

68 (59%)

39 (59%)

32 (55%)

0.06

 Statin

65 (56%)

25 (58%)

19 (48%)

64 (51%)

40 (61%)

35 (60%)

0.11

 Aspirin

2 (2%)

2 (5%)

1 (3%)

5 (4%)

9 (14%)

8 (14%)

0.90

 Insulin

36 (31%)

16 (37%)

13 (33%)

32 (25%)

20 (30%)

14 (25%)

0.54

 Oral antidiabetic

23 (20%)

10 (23%)

8 (20%)

23 (18%)

14 (21%)

9 (16%)

0.28

 Erythropoietin

8 (7%)

8 (12%)

2 (5%)

11 (9%)

7 (11%)

6 (10%)

0.36

 Iron

2 (2%)

3 (7%)

1 (3%)

7 (6%)

7 (11%)

6 (10%)

0.77

 Vitamin D

19 (16%)

11 (26%)

11 (28%)

13 (10%)

18 (27%)

16 (28%)

0.13

  1. *Significant p-value of the interaction between time and random group: significant p-value means a difference in the evolution of the 2 groups
  2. Continuous variables are expressed as mean (SD) or median (IQR) depending on distribution. Categorical variables are expressed as n (%)
  3. T0, T1 and T2 represent baseline and follow-up at one and two years respectively
  4. aAs some patients did not have follow-up echocardiography, results are expressed as n/n (%)